ANP 2.99% 6.5¢ antisense therapeutics limited

genasense implications

  1. 140 Posts.
    Genta Inc will hold an open meeting for investors and analysts in New York on Wednesday (NY Time), at which it will present an update on results of the
    Phase 3 Randomised Clinical Trial of Genasense(TM) (oblimersen sodium).

    PARIS, Sept 8 (Reuters) - Franco-German drugmaker Aventis (AVEP.PA) said on Monday it expected to decide in coming weeks whether to apply this year
    for U.S. marketing approval for cancer drug Genasense, which it is developing with Genta Inc.

    "We anticipate in a matter of weeks to be in a position to determine whether we can file this year for one of the three lead indications," Aventis Vice President for Drug Innovation Frank Douglas said during a conference call after the company said it had bought rights to another experimental cancer drug.

    Will keep an eye out for this one.
 
watchlist Created with Sketch. Add ANP (ASX) to my watchlist
(20min delay)
Last
6.5¢
Change
-0.00(2.99%)
Mkt cap $24.89M
Open High Low Value Volume
6.5¢ 6.7¢ 5.8¢ $1.189M 18.87M

Buyers (Bids)

No. Vol. Price($)
1 1000 6.5¢
 

Sellers (Offers)

Price($) Vol. No.
6.6¢ 250000 2
Last update - 12.09pm 23/10/2018 (20 minute delay) ?
(live)
Last
6.2¢
  Change
-0.00 ( 8.28 %)
Open High   Low Volume
6.5¢ 6.7¢   5.9¢ 18648111
Last updated 12.31pm 23/10/2018 (live) ?
ANP (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.